Crimean-Congo haemorrhagic fever
Crimean-Congo haemorrhagic fever (CCHF) is a viral disease spread mainly by infected ticks and contact with infected animal blood or tissues. People working with livestock, including farmers, butchers and veterinarians, face particular exposure risks. The virus can also pass between people through contact with infected blood or other bodily fluids, including during health care. Infected livestock usually show no obvious illness. CCHF begins suddenly with fever, headache and muscle pain. Some patients develop bleeding and serious damage to the liver, kidneys or lungs. WHO reports that 10–40% of reported cases die, although the proportion varies between outbreaks. Early intensive supportive care can improve survival. There is no approved specific treatment; the benefit of the antiviral ribavirin remains uncertain. The sources reviewed do not establish a widely available licensed vaccine. Prevention therefore centres on avoiding tick bites, safer handling of animals and their tissues, and preventing exposure to patients’ blood and bodily fluids. The disease occurs across parts of Africa, Europe, the Middle East and Asia.
Key facts
| Transmission | Infected tick bites; contact with infected animal blood or tissues, especially during slaughter; contact with infected people's blood, secretions or other bodily fluids. Health-care-associated transmission can occur. |
|---|---|
| Incubation | After a tick bite: usually 1–3 days, maximum 9 days. After contact with infected blood or tissues: usually 5–6 days, documented maximum 13 days. |
| Case fatality | WHO gives a general range of 10–40%. In Iraq, 13 of 97 laboratory-confirmed cases died during 2022-01-01 to 2022-05-22, reported by WHO as 13%. The reviewed sources do not establish separate treated and untreated rates. |
| Reproduction number | unknown |
| Vaccine | No widely available licensed vaccine is established by the reviewed sources. A 2023 review reports no licensed vaccines; WHO's 2022 Iraq notice reports no vaccine available for people or animals. |
| Treatment | Early intensive supportive care, including fluid management and treatment of specific symptoms. No approved specific treatment. Ribavirin is used off label, but its effect on survival remains uncertain. |
| Reservoir | A tick–animal–tick cycle involving wild and domestic animals, including cattle, sheep and goats. Hyalomma ticks are the principal vector; infected livestock usually show no apparent disease. |
| Endemic regions | Parts of Africa, the Balkans, the Middle East and Asia; the 2023 literature review also describes southern and eastern Europe. |
Transmission
CCHF reaches people mainly through infected tick bites or contact with infected animal blood and tissues. Slaughtering and handling livestock are important exposure settings. Farmers, slaughterhouse workers and veterinarians are among the groups most often affected. Animals can carry the virus without looking ill, so appearance alone cannot establish that handling them is safe. Hyalomma ticks are the main carriers between animals and people. Human-to-human transmission is also possible through contact with infected blood, secretions or other bodily fluids. In hospitals, contaminated equipment, reused needles and inadequate infection-control measures can spread infection. The reviewed sources do not provide an established reproduction number or secondary attack rate.
- Crimean-Congo haemorrhagic fever WHO
- Crimean-Congo haemorrhagic fever. Europe PMC · 1 Apr 2006
Symptoms and severity
Symptoms usually begin suddenly. They include fever, headache, muscle aches, dizziness and sensitivity to light. Nausea, vomiting, diarrhoea and abdominal pain may occur early, followed by confusion or marked sleepiness. Bleeding can appear as small spots in the skin or mouth and may become more extensive. Severe illness can damage the liver, kidneys or lungs. After a tick bite, symptoms usually start within 1–3 days, with a maximum of 9 days. After exposure to infected blood or tissues, the usual interval is 5–6 days, with a documented maximum of 13 days. WHO gives a case-fatality range of 10–40%. This is a proportion among reported cases, not a fixed prediction for an individual patient.
- Crimean-Congo haemorrhagic fever WHO
- Crimean-Congo Hemorrhagic Fever - Iraq WHO · 1 Jun 2022
Treatment and vaccines
Early intensive supportive care can improve the chance of survival. This includes managing fluids and treating the specific problems caused by the illness. WHO states that no specific treatment is approved for CCHF. Ribavirin, an antiviral medicine, has been given off label, but evidence that it improves patient outcomes remains uncertain. WHO recommends studying it and other investigational treatments in randomized clinical trials whenever possible. The 2023 review reports no licensed vaccines, while WHO's 2022 Iraq notice states that no vaccine was available for people or animals. These sources do not establish a broadly available vaccination option. Preventing tick bites, reducing contact with infected animal tissues and protecting health workers therefore remain central.
- Crimean-Congo haemorrhagic fever WHO
- Crimean-Congo Hemorrhagic Fever - Iraq WHO · 1 Jun 2022
- Crimean-Congo haemorrhagic fever virus. Europe PMC · 14 Mar 2023
Where it occurs
CCHF occurs across parts of Africa, the Balkans, the Middle East and Asia. A 2023 review also describes cases in southern and eastern Europe. Its distribution is closely linked to the ticks that transmit it, especially Hyalomma ticks. Risk is not uniform across these large regions: local tick populations, livestock exposure and working practices matter. Iraq is an endemic country, meaning the infection is established there rather than appearing only through imported cases. WHO reports that it was first diagnosed there in 1979. Wild and domestic animals help maintain the infection cycle, usually without obvious illness. The 2023 review warns that the expanding range of Hyalomma ticks is placing new populations at risk.
- Crimean-Congo haemorrhagic fever WHO
- Crimean-Congo Hemorrhagic Fever - Iraq WHO · 1 Jun 2022
- Crimean-Congo haemorrhagic fever virus. Europe PMC · 14 Mar 2023
Recent history
Open Outbreak's archive contains nine CCHF events, with entries spanning 1996–2022. They cover South Africa, Afghanistan, Pakistan, Russia, Kosovo, Mauritania, Turkey and Iraq. These are archived events, not a complete count of outbreaks worldwide; WHO sometimes issued several notices about one event. The latest WHO item returned in this search is dated 2022-06-01 and concerns Iraq. Between 2022-01-01 and 2022-05-22, authorities reported 212 cases: 115 suspected and 97 laboratory-confirmed. There were 27 deaths, including 13 among confirmed cases. WHO noted substantially more confirmed cases than in 2021 and pressure on health services. No later WHO item was returned, so this page does not establish the outbreak situation on 2026-11-15.
- 1996 - Crimean-Congo Haemorrhagic Fever in South Africa WHO Disease Outbreak News · 5 Nov 1996
- 1998 - Crimean-Congo haemorrhagic fever in Afghanistan WHO Disease Outbreak News · 8 May 1998
- 1998 - Crimean-Congo haemorrhagic fever in Pakistan WHO Disease Outbreak News · 8 May 1998
- 1999 - Crimean-Congo haemorrhagic fever, Russian Federation (update) WHO Disease Outbreak News · 26 Jul 1999
What to watch
Important warning signals include locally acquired cases in new regions, expanding populations of the main tick vector, and rising cases among people who handle livestock. Clusters among health workers or household contacts would raise concern about human-to-human transmission and failures in infection control. This transmission route is already known; it would not by itself represent a new property of the virus. WHO's Iraq assessment highlights animal movements and increased slaughter as circumstances that can increase exposure. Reliable testing, surveillance and timely outbreak response are essential. Treatment trials and vaccine developments also deserve attention, because current options are limited. The reviewed sources do not identify antiviral resistance as a demonstrated driver of outbreaks or establish an existing broad vaccine supply to monitor.
- Crimean-Congo Hemorrhagic Fever - Iraq WHO · 1 Jun 2022
- Crimean-Congo haemorrhagic fever WHO
- Crimean-Congo haemorrhagic fever virus. Europe PMC · 14 Mar 2023